120 related articles for article (PubMed ID: 22790919)
1. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions.
Hooper CE; Morley AJ; Virgo P; Harvey JE; Kahan B; Maskell NA
Eur Respir J; 2013 Jan; 41(1):18-24. PubMed ID: 22790919
[TBL] [Abstract][Full Text] [Related]
2. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
Davies HE; Sadler RS; Bielsa S; Maskell NA; Rahman NM; Davies RJ; Ferry BL; Lee YC
Am J Respir Crit Care Med; 2009 Sep; 180(5):437-44. PubMed ID: 19299498
[TBL] [Abstract][Full Text] [Related]
4. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Grigoriu B; Chahine B; Zerimech F; Grégoire M; Balduyck M; Copin MC; Devos P; Lassalle P; Scherpereel A
Clin Biochem; 2009 Jul; 42(10-11):1046-50. PubMed ID: 19302997
[TBL] [Abstract][Full Text] [Related]
5. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
Creaney J; Yeoman D; Naumoff LK; Hof M; Segal A; Musk AW; De Klerk N; Horick N; Skates SJ; Robinson BW
Thorax; 2007 Jul; 62(7):569-76. PubMed ID: 17356060
[TBL] [Abstract][Full Text] [Related]
6. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
9. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
[TBL] [Abstract][Full Text] [Related]
10. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
12. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
[TBL] [Abstract][Full Text] [Related]
15. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
Alemán C; Manuel Porcel J; Ma Segura R; Alegre J; Esquerda A; Ruiz E; Bielsa S; de Sevilla TF
Med Clin (Barc); 2009 Oct; 133(12):449-53. PubMed ID: 19783262
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
[TBL] [Abstract][Full Text] [Related]
19. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
